1. Introduction {#sec1}
===============

Atherosclerosis (AS) is a multifactorial, progressive disease and a major global cause of morbidity and mortality. Atherosclerosis-related cardiovascular diseases, such as coronary artery disease (CAD), acute myocardial infarction (AMI), and ischemic cerebrovascular disease (ICVD), are the causes of death in almost 50% of cases in developed countries \[[@B1]\]. The exact mechanisms of AS are indistinct. Many studies indicate that the genetic factors play a significant role in the development of AS \[[@B2]--[@B5]\]. Until recently, much attention has been focused on this field, and the association of the Fractalkine (FKN) receptor (CX3CR1) gene polymorphisms and AS has been extensively studied \[[@B6]--[@B31]\].

It has recently been accepted that AS is predominantly an inflammatory process \[[@B32], [@B33]\] and begins with a fatty streak, which is made up almost entirely of monocyte-derived macrophages \[[@B33], [@B34]\]. During the process of vascular inflammation, chemokines and adhesive molecules exert a vital role via mediating the activation of inflammatory cells and their aggregation or adhesion to vascular walls \[[@B35], [@B36]\]. FKN is a special chemotactic factor existing in both membrane-bound and soluble forms \[[@B37]\]; the expression of FKN and its receptor CX3CR1 is upregulated in AS lesions \[[@B38]--[@B40]\], and the severity of AS is greatly improved by inhibiting their expression \[[@B40]--[@B42]\], suggesting that the FKN/CX3CR1 is closely correlated to AS. Given the crucial role of*CX3CR1* in the inflammatory process, the mutations in the*CX3CR1* may also play a significant role in the development of atherosclerotic diseases. Recently, a number of molecular epidemiological studies have been done to evaluate the associations between the*CX3CR1* gene polymorphisms (T280M and V249I) and the risk of atherosclerotic diseases \[[@B6]--[@B31]\]. However, the results of different studies are inconsistent, possibly due to small sample sizes in the individual studies. In 2009, Apostolakis et al. \[[@B43]\] performed a meta-analysis to evaluate the association between the*CX3CR1* T280M and V249I polymorphisms and CAD and demonstrated that the*CX3CR1* 280M allele was associated with a reduced risk of CAD in the heterozygous state and 249I-280M haplotype had a atheroprotective effect on CAD. However, they just studied the 280M allele and 249I-280M haplotype of*CX3CR1* in Caucasians. Considering the meta-analysis only focused on the association of the*CX3CR1* polymorphism with the single atherosclerotic disease, we, therefore, performed this meta-analysis of all the studies available now to get a more precise estimation of the associations between the*CX3CR1*T280 M (rs3732378) and V249I (rs3732379) polymorphisms and overall AS risk.

2. Materials and Methods {#sec2}
========================

2.1. Literature Search and Selection {#sec2.1}
------------------------------------

This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria \[[@B44]\]. Eligible literatures published before the end of March 1, 2014, were identified by the search of PubMed, Embase, Web of Science, Medline, Cochrane database, and CNKI. Library uses combinations of the following keywords: "chemokine receptor 1" or "FKN" or "CX3CR1" or "fractalkine" and "polymorphism" or "mutation" or "variant" or "variation" or "genotype" and "coronary artery disease" or "CAD" or "coronary heart disease" or "CHD" or "myocardial infarction" or "MI" or "ischemic cardiovascular disease" or "ischemic cardiovascular events" or "ischemic stroke" or "IS" or "cerebrovascular disease" or "ischemic cerebrovascular events" or "cerebral infarction" or "cerebral ischemia" or "brain infarction" or "carotid artery stenosis" or "CAAD" or "transient ischemic attack" or "TIA" or "peripheral arterial disease" or "PAD" or "peripheral artery occlusive disease" or "PAOD" or "renal artery stenosis" or "RAS" or "retinal artery occlusion" or "RAO" or "aortic aneurysm" or "atherosclerosis". In addition, all references cited were reviewed to identify additional studies. If two or more studies sharing the same studied populations, the one with the small size was abandoned. Two reviewers (JW and QZL) searched the above databases independently. Decisions were compared and disagreements about study selection were resolved by involving a third reviewer (RXY). The search was limited to English and Chinese language papers. There was no restriction on time period, sample size, or population.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

To be included in the present meta-analysis, the studies had to comply with the following major criteria: (1) case-control or cohort studies evaluating the associations between the*CX3CR1* T280M and V249I polymorphisms and AS risk; (2) published studies with full text articles; (3) sufficient published data for calculating odds ratios (ORs) with their 95% confidence intervals (CIs); (4) study population being adults; (5) the diagnosis of ischemic heart disease (CAD and AMI) being accorded with the result of coronary angiography, criteria of World Health Organization (WHO), criteria of European Society of Cardiology (ESC), or criteria of American College of Cardiology/American Heart Association (ACC/AHA); the diagnosis of ICVD is accorded with result of computed tomography (CT) or magnetic resonance imaging (MRI); the diagnosis of carotid atherosclerosis (CAA) was assessed by ultrasound color Doppler (USCD), and peripheral arterial disease (PAD) was diagnosed by the following criteria: clinical symptoms of PAD (intermittent claudication, rest pain, or gangrene) accompanied by an ankle-brachial-index and significant stenosis of leg arteries confirmed by FCDS and/or angiography.

Studies were excluded if they were (1) review or meta-analysis; (2) not conducted in humans; (3) duplicate studies.

2.3. Data Extraction {#sec2.3}
--------------------

Data, including name of the first author, year of publication, study population (country, ethnicity), study type (case-control and cohort study), type of atherosclerotic disease, source of controls (population-based studies and hospital-based studies), sample size (total numbers of cases and controls), and number of genotypes in cases and controls, were extracted from each study by two reviewers independently (JW and QZL) according to the prespecified inclusion criteria. Studies that reported a comparison of two case samples, such as different age groups, were included in the meta-analysis as independent studies. Decisions were compared and disagreements about study selection were resolved by consensus or by involving a third reviewer (RXY).

2.4. Quality Assessment for Individual Studies {#sec2.4}
----------------------------------------------

The quality of the individual studies was evaluated and scored by two reviewers independently based on the Newcastle-Ottawa Scale (NOS) \[[@B45]\]. Each study was assessed based on three broad perspectives: selection, comparability, and exposure, and each satisfactory answer received one point. The NOS ranges between zero (none of the quality criterion was met) up to nine stars (all the quality criteria were met), and the high-quality study was considered as the one with a score higher than six. The reviewer (RXY) examined the results, and a consensus was reached.

2.5. GRADE Quality Assessment {#sec2.5}
-----------------------------

GRADE (grades of recommendation, assessment, development and evaluation) approach was adopted to grade quality of evidence for each association \[[@B46]\]. The GRADE system included level of evidence: (1) high quality, we are very confident that the true effect lies close to that of the estimate of the effect; (2) moderate quality, we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; (3) low quality, our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect; and (4) very low quality, we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. Two reviewers (JW and QZL) assessed quality independently and solved disagreement by discussion.

2.6. Statistical Analysis {#sec2.6}
-------------------------

For the controls of each study, Hardy-Weinberg equilibrium (HWE) was assessed using the chi-square test (*P* \< 0.05 was considered significant deviation from HWE). We performed a haplotype analysis based on the genotype data, the haplotype frequencies were calculated by CubeX analysis software for each study separately and for the whole sample \[[@B47]\]. The strength of associations between the*CX3CR1* T280M and V249I polymorphisms and AS risk was assessed by ORs with 95% CIs. The pooled ORs were performed for dominant model (T/M + M/M*versus*T/T for T280M; V/I + I/I*versus*V/V for V249I), recessive model (M/M*versus*T/T + T/M for T280M; I/I*versus*V/V + V/I for V249I), codominant model (T/M*versus*T/T + M/M for T280M; V/I*versus*V/V + I/I for V249I), additive model (M/M*versus*T/T for T280M; I/I*versus*V/V for V249I), and allelic model (M allele*versus* T allele for T280M; I allele*versus* V allele for V249I). Bonferroni correction was used to control for the multiple testing in view of five genetic models under investigation (significance was set at 0.05/5 = 0.01), then another statistical significance was set as *P* \< 0.05.

Heterogeneity across individual studies was calculated using Cochran\'s *Q* statistic (*P* ~*Q*~) and the *I* ^2^ statistic. Values for *P* ~*Q*~ \< 0.10 and *I* ^2^ \> 50% indicate a presence of heterogeneity among studies \[[@B48], [@B49]\], and the random-effects model was used for the meta-analysis. Otherwise, the fixed-effects model was used. Subgroup analysis was used to alleviate the heterogeneity based on ethnicity (Asian and Caucasians), the type of disease (CAD, ICVD, CAA, and PAD), and source of controls (population-based and hospital-based).

Sensitivity analyses were performed based on HWE (studies without HWE were excluded) and NOS score (studies with score ≤ 6 were excluded). Begg\'s funnel plot and Egger\'s regression test were conducted to identify possible publication bias in the current meta-analysis (*P* \< 0.05 was considered representative of statistically significant publication bias). The analyses were performed using Stata software11.0 (StataCorp LP, College Station, USA).

3. Results {#sec3}
==========

3.1. Study Characteristics {#sec3.1}
--------------------------

The present study met the PRISMA statements and PRISMA flow chart (Checklist S1 available online at <http://dx.doi.org/10.1155/2014/913678> and [Figure 1](#fig1){ref-type="fig"}). A total of 667 articles were identified after searching. After careful review, 26 articles involving 49 studies (24 studies for T280M and 25 studies for V249I polymorphisms) met the inclusion criteria and were selected in this meta-analysis \[[@B6]--[@B31]\]; one duplicate study was cut \[[@B18]\]. For the*CX3CR1* T280M polymorphism, 7732 AS cases and 5905 controls were included to assess the association between the variant and AS risk \[[@B6]--[@B12], [@B15]--[@B19], [@B21]--[@B28], [@B30], [@B31]\]. For the*CX3CR1* V249I polymorphism, 7952 AS cases and 6035 controls were included to assess the association between the variant and AS risk \[[@B6]--[@B12], [@B15]--[@B24], [@B26]--[@B31]\]. Main characteristics of the included studies were listed in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}. The most commonly atherosclerotic disease included in the present meta-analysis was CAD in 21 studies. In addition, there were 8 studies involving carotid atherosclerosis, 8 studies involving cerebral infarction, 6 studies involving AMI, 2 studies involving ICVD, 2 studies involving ischemic stroke (IS), and 2 studies involving PAD. There were 24 studies of Asians and 25 studies of Caucasians. Three studies did not follow the HWE \[[@B8], [@B23], [@B26]\]. The results of GRADE were shown in Table S1.

3.2. Genotype-Phenotype Association {#sec3.2}
-----------------------------------

As shown in [Table 2](#tab2){ref-type="table"}, the overall results showed no significant association between the*CX3CR1* T280M polymorphism and the susceptibility to AS in five genetic models (*P* \> 0.01 for all). When we performed a subgroup analysis, there was significant association between T280M polymorphism and the susceptibility to AS in the CAD group in dominant model (*P* \< 0.01), codominant model (*P* \< 0.01), additive model (*P* \< 0.01), and allelic model (*P* \< 0.01), but not in recessive model (*P* \> 0.01), suggesting that the 280M allele carriers decreased the risk of CAD in the heterozygous state. The significant association between T280M polymorphism and the susceptibility to AS was also found in the ICVD group in recessive model (*P* \< 0.01) and additive model (*P* \< 0.01), but not in dominant model (*P* \> 0.01), codominant model (*P* \> 0.01), or allelic model (*P* \> 0.01), suggesting that the 280M allele carriers increased the risk of ICVD in homozygote state. Then, we considered the TT genotype as the baseline risk, we found TM genotype was a protective role for AS (OR = 0.81, 95% CI = 0.66--0.99, *P* = 0.04; [Table 3](#tab3){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}), subgroup analysis showed that the TM genotype was a protective role for CAD (OR = 0.67, 95% CI = 0.52--0.87, *P* \< 0.01; [Table 3](#tab3){ref-type="table"} and Figure S1), and MM genotype was a risk factor for ICVD (OR = 2.88, 95% CI = 1.64--5.04, *P* \< 0.001; [Table 3](#tab3){ref-type="table"} and Figure S2). There was no association between the T280M polymorphism and the susceptibility to AS in the other groups (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}).

The overall results showed no significant association between the*CX3CR1* V249I polymorphism and the susceptibility to AS in five genetic models (*P* \> 0.01 for all, [Table 2](#tab2){ref-type="table"}). Subgroup analysis showed significant association between V249I polymorphism and the susceptibility to AS in CAD group in dominant model (*P* \< 0.01), codominant model (*P* \< 0.01), additive model (*P* \< 0.01), and allelic model (*P* \< 0.01), but not in recessive model (*P* \> 0.01), suggesting that the 249I alleles decreased the risk of CAD in heterozygote state. Significant associations were also found between this variant and the susceptibility to AS in the population-based (PB) group in recessive and additive models (*P* \< 0.01 for each). Then, we considered the VV genotype as the baseline risk; we found VI genotype was a protective role for AS (OR = 0.84, 95% CI = 0.72--0.98, *P* = 0.02; [Table 3](#tab3){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}); subgroup analysis showed that the VI genotype was a protective role for CAD (OR = 0.72, 95% CI = 0.59--0.90, *P* \< 0.01; [Table 3](#tab3){ref-type="table"} and Figure S3). There was no association between V249I polymorphism and the susceptibility to AS in the other groups (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}).

For V249I-T280M combined genotype (Table S2), when we took VVTT genotype as a baseline risk, significant discrepancies were found in VVTM genotype (OR = 11.95, 95% CI = 5.00--28.58, *P* \< 0.001; [Table 3](#tab3){ref-type="table"}), suggesting that the VVTM genotype was a risk factor for AS, but VVTM was a very rare genotype and may not have potential clinical significance. Significant association was also found in the VITM (OR = 0.64, 95% CI = 0.50--0.82, *P* \< 0.001) and IITM genotypes (OR = 0.69, 95% CI = 0.52--0.90, *P* \< 0.01), suggesting that the VITM and IITM genotypes were protective roles for AS ([Table 3](#tab3){ref-type="table"}).

3.3. Linkage Disequilibrium Analysis {#sec3.3}
------------------------------------

There were nine combined genotypes in Table S2; six studies identified the extremely rare VVTM genotype. Linkage disequilibrium (LD) analysis showed a strong association between the T280M and V249I polymorphisms ([Table 4](#tab4){ref-type="table"}). Thirteen of the fourteen studies conclusively found complete LD; an association analysis of the whole sample (cases and controls) indicated strong (but not complete) LD between the two loci (*D*′ = 0.9950,  *r* ^2^ = 0.5394).

3.4. Haplotype-Phenotype Association {#sec3.4}
------------------------------------

Haplotype frequencies of each study and the total sample are reported in [Table 4](#tab4){ref-type="table"}, the strong LD between the V249I and T280M polymorphisms resulted in three predominant haplotypes and the extremely rare 249V-280M; the latter haplotype accounts for less than 0.5% of the entire population\'s gene pool. We assessed the effect of the 249V-280M, 249I-280T, and 249I-280M haplotypes on the risk for AS independently taking the 249V-280T haplotype as a baseline risk. A significant predominance of the 249I-280M haplotype was observed in the control population compared to case subjects (OR = 0.63, 95% CI: 0.50--0.81, *P* \< 0.001; [Table 3](#tab3){ref-type="table"}). No association was observed between the 249I-280T haplotype and susceptibility to AS (OR = 1.09, 95% CI: 0.97--1.21, *P* = 0.14; [Table 3](#tab3){ref-type="table"}).

3.5. Sensitivity Analysis {#sec3.5}
-------------------------

Sensitivity analyses were conducted to determine whether modification of the inclusion criteria of the meta-analysis affected the final results. The included studies were limited to those conforming to HWE or the high quality studies (NOS score ≥ 7); the corresponding pooled ORs were not materially altered, either for the*CX3CR1* T280M polymorphism or for the V249I polymorphism. This suggested that the overall results of this meta-analysis were statistically robust. The main results of sensitivity analyses are shown in [Table 2](#tab2){ref-type="table"}.

3.6. Heterogeneity Analysis {#sec3.6}
---------------------------

For both*CX3CR1*T280M and V249I polymorphisms, significant heterogeneity existed in the overall comparisons in five genetic models. We performed subgroup analyses based on the ethnic (Caucasians and Asian), atherosclerotic diseases (CAD, PAD, CAA, and ICVD), and source of control (hospital-based or population-based); heterogeneity was distinctly reduced; although it was still significant, we could not point out other possible sources of heterogeneity. The data were shown in Table S3.

For the V249I-T280M combined polymorphism, when the VVTT genotype was taken as the baseline risk, we found significant heterogeneity in the VITM genotype (*P* ~*Q*~ \< 0.1, *I* ^2^ = 69.2%). When the 249V-280T haplotype was taken as the baseline risk, we showed obvious heterogeneity in the 249I-280 M haplotype (*P* ~*Q*~ \< 0.1, *I* ^2^ = 82.2%; [Table 3](#tab3){ref-type="table"}).

3.7. Publication Bias {#sec3.7}
---------------------

Begg\'s funnel plot and Egger\'s regression test were performed to assess potential publication bias. For the*CX3CR1* T280M polymorphism, visual inspection of the funnel plot ([Figure 4(a)](#fig4){ref-type="fig"}) displays symmetrical distribution of OR estimations, suggesting no publication bias. In addition, the results of Egger\'s regression test also provided evidence for no publication bias (TM*versus* TT, *P* \> 0.05 for all genetic models). For the*CX3CR1* V249I polymorphism, no obvious asymmetry was observed in any genetic model according to the visual assessment of funnel plot ([Figure 4(b)](#fig4){ref-type="fig"}). The results of Egger\'s regression test did not provide any statistical evidence for publication bias (VI*versus* VV, *P* \> 0.05 for all genetic models).

4. Discussion {#sec4}
=============

In this study, twenty-five articles involving the associations between the*CX3CR1*polymorphisms and AS risk were included in the final meta-analysis. According to the GRADE approach, the quality of the evidence of*CX3CR1* T280M polymorphism was very low in dominant model and allelic model, moderate in recessive model and additive model, and low in codominant model (Table S1). For the*CX3CR1* V249I polymorphism, GRADE suggested that the quality of the evidence was moderate in recessive model, codominant model, and additive model, low in dominant model, and very low in allelic model (Table S1).

The overall findings showed that there was no association between the*CX3CR1* polymorphisms and the risk of AS in five genetic models. To make a more comprehensive analysis, subgroup analyses were performed based on ethnicity, atherosclerotic disease, and source of controls. For the*CX3CR1* T280M polymorphism, Apostolakis et al. \[[@B43]\] showed that the 280M allele carriers reduced the risk of CAD in heterozygote state. In the present study, we also found atheroprotective effect to AS in the CAD group. In addition, we found that the 280M allele carriers increased the risk of ICVD in homozygote state. For the*CX3CR1* V249I polymorphism, significant associations were found between this variant and the atheroprotective effect on AS in CAD and PB groups. These results suggested that the 249I allele carriers reduced the risk of CAD in heterozygote state. The above statistical results were based on Bonferroni correction to control for the multiple testing in view of under investigation.

For the combined genotype, the VITM and IITM genotypes played an atheroprotective effect on AS. The combined VVTM genotype was more common in the cases than in the controls; however, the rarity of the VVTM genotype makes any conclusion rather unsafe. LD analysis indicated a strong association between T280M and V249I, and a protective role of the 249I-280M haplotype was also observed in the control population compared to case subjects. No association was observed between the 249I-280T haplotype and the susceptibility to AS. These results were consistent with those of a previous study \[[@B43]\].

Considering the studies without HWE or with low NOS score may influence the overall results, subsequent sensitivity analyses restricted to the studies with HWE or high NOS score were performed, but no corresponding pooled OR was materially altered in the dominant, recessive, codominant, additive, and allelic models. These results suggested that the studies without HWE or low score should not be considered as a factor influencing the overall results.

Heterogeneity of the included studies is the most important drawback when the genotypic data were analyzed, either for the*CX3CR1* T280M or for the*CX3CR1* V249I polymorphism. Heterogeneity should not be ignored and should be carefully factored in the interpretation of the final results. For the*CX3CR1* T280M and V249I polymorphisms, the heterogeneity can partly be explained by the ethnicity (Caucasians and Asian), subtype of atherosclerotic diseases (CAD, CAA, and ICVD), and source of control (hospital-based and population-based).

However, some limitations of this meta-analysis should be acknowledged. Firstly, there was significant heterogeneity in this meta-analysis. Heterogeneity may affect the precision of overall results, despite the use of appropriate meta-analytic techniques with random-effects model. Secondly, in the subgroup analyses, the sample sizes in some subgroup, such as the PAD and CAA groups of the*CX3CR1* T280M and V249I polymorphisms, were relatively small, not having enough statistical power to explore the real association. Thirdly, AS is a complex disease and involves potential interactions of gene-environment. However, many eligible studies included in this meta-analysis did not consider the environmental factors. Therefore, studies with larger sample sizes and better design are needed.

5. Conclusion {#sec5}
=============

The present meta-analysis suggested that the*CX3CR1* 280M and 249I allele carriers had atheroprotective roles on AS in heterozygote state, and the 280M allele carriers were associated with the susceptibility to AS in homozygote state. The combined genotypes of VITM and IITM also had atheroprotective roles on AS. Consequently, this effect may be attributed to the haplotype of 249I-280M. However, the results should be interpreted with caution because of its limitations. Further studies with large sample size, especially with the consideration of gene-gene and gene-environment interactions, are needed to confirm our findings.
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###### 

Characteristics of studies included in this meta-analysis.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Position                      First author        Year      Country   Study type   Disease   Source of control   SS (Case/Control)   Genotypes distribution (case/control)   HWE\        Score                                          
                                                                                                                                                                               Y/N (*P*)                                                  
  ----------------------------- ------------------- --------- --------- ------------ --------- ------------------- ------------------- --------------------------------------- ----------- ----------- ---------- ----------- ----------- ---
  T280M                         Moatti \[[@B15]\]   2001      France    CCS          CAD       HB                  151/249             123/179                                 25/65       3/5         271/423    31/75       Y (0.748)   8

  Gugl \[[@B8]\]                2003                Austria   CCS       PAD          HB        492/503             333/326             143/165                                 16/12       809/817     175/189    Y (0.093)   8           

  Ghilardi \[[@B7]\]            2004                Italia    CCS       CAA          HB        108/204             87/142              18/58                                   3/4         192/342     24/66      Y (0.490)   8           

  Lavergne \[[@B10]\]           2005                France    CCS       CI           HB        460/469             314/338             125/123                                 21/8        753/799     167/139    Y (0.400)   7           

  Niessner \[[@B17], [@B18]\]   2005                Austria   CCS       CAD          HB        720/432             514/319             189/100                                 17/13       1217/738    223/126    Y (0.141)   7           

  Apostolakis \[[@B43]\]        2007                Greece    CCS       CAD          HB        210/165             159/109             48/53                                   3/3         366/271     54/59      Y (0.228)   7           

  An \[[@B24]\]                 2008                China     CCS       CAD          HB        108/80              88/59               18/20                                   2/1         194/138     22/22      Y (0.629)   6           

  Nassar-a \[[@B16]\]           2008                Canada    CCS       CAD          PB        149/149             97/94               49/48                                   3/7         243/236     55/62      Y (0.784)   8           

  Nassar-b \[[@B16]\]           2008                Canada    CCS       CAD          PB        150/149             92/94               49/48                                   9/7         233/236     67/62      Y (0.784)   8           

  Peng \[[@B25]\]               2008                China     CCS       ICVD         PB        165/150             138/143             25/7                                    2/0         301/293     29/7       Y (0.770)   8           

  Zheng \[[@B31]\]              2008                China     CCS       CAA          HB        117/93              77/73               32/17                                   8/3         186/163     48/23      Y (0.131)   6           

  Kimouli \[[@B9]\]             2009                Greece    CCS       CAA          PB        150/151             112/87              31/58                                   7/6         255/232     45/70      Y (0.334)   8           

  Matzhold \[[@B12]\]           2009                Austria   CCS       CAD          PB        2565/728            1797/483            706/217                                 59/26       4300/1183   824/269    Y (0.790)   7           

  Xiao \[[@B28]\]               2010                China     CCS       CAD          PB        139/90              129/81              10/9                                    0/0         268/171     10/9       Y (0.618)   7           

  Zhang \[[@B30]\]              2010                China     CCS       CI           PB        120/102             98/71               20/30                                   2/1         216/172     24/32      Y (0.258)   7           

  Zhao \[[@B23]\]               2010                China     CCS       CAA          HB        318/292             246/201             56/70                                   16/21       548/472     88/112     N (0.000)   7           

  Li \[[@B11]\]                 2012                China     CCS       CI           PB        308/294             284/280             24/14                                   0/0         592/574     24/14      Y (0.676)   8           

  Shi \[[@B26]\]                2012                China     CCS       CI           HB        563/563             493/518             50/38                                   20/7        1036/1074   90/52      N (0.000)   7           

  Singh-a \[[@B21], [@B22]\]    2012                India     CCS       CAD          PB        152/300             126/191             24/99                                   2/10        276/481     28/119     Y (0.513)   8           

  Singh-b \[[@B21], [@B22]\]    2012                India     CCS       CAD          PB        156/300             124/191             28/99                                   4/10        276/481     36/119     Y (0.513)   8           

  Singh-c \[[@B21], [@B22]\]    2012                India     CCS       AMI          PB        230/300             190/191             36/99                                   4/10        416/481     44/119     Y (0.513)   7           

  Wu \[[@B27]\]                 2012                China     CCS       IS           PB        163/100             135/95              26/5                                    2/0         296/195     30/5       Y (0.798)   7           

  Pucci-a \[[@B19]\]            2013                Italy     CCS       AMI          HB        25/22               21/14               4/7                                     0/1         46/35       4/9        Y (0.917)   7           

  Pucci-b \[[@B19]\]            2013                Italy     CCS       AMI          HB        16/22               9/14                7/7                                     0/1         25/35       7/9        Y (0.917)   7           

                                                                                                                                                                                                                                          

  Position                      First\              Year      Country   Study type   Disease   Source of control   SS (case/control)   Genotypes distribution (case/control)   HWE\        Score                                          
                                author                                                                                                                                         Y/N (*P*)                                                  

  V/V                           V/I                 I/I       V         I                                                                                                                                                                 

                                                                                                                                                                                                                                          

  V249I                         Moatti \[[@B15]\]   2001      France    CCS          CAD       HB                  151/249             97/126                                  47/104      7/19        241/356    61/142      Y (0.699)   8

  Gugl \[[@B8]\]                2003                Austria   CCS       PAD          HB        492/503             261/268             198/210                                 33/25       720/746     264/260    N (0.045)   8           

  Ghilardi \[[@B7]\]            2004                Italia    CCS       CAA          HB        108/204             63/108              34/84                                   11/12       160/300     56/108     Y (0.409)   8           

  Lavergne \[[@B10]\]           2005                France    CCS       CI           HB        458/468             234/236             178/203                                 46/29       646/675     270/261    Y (0.089)   7           

  Niessner \[[@B17], [@B18]\]   2005                Austria   CCS       CAD          HB        720/432             395/246             271/161                                 54/25       1061/653    379/211    Y (0.842)   7           

  Rios \[[@B20]\]               2005                Brazil    CS        CAD          HB        219/129             120/72              80/51                                   19/6        320/195     118/63     Y (0.420)   7           

  Apostolakis \[[@B43]\]        2007                Greece    CCS       CAD          HB        210/165             111/86              81/59                                   18/20       303/231     117/99     Y (0.056)   7           

  An \[[@B24]\]                 2008                China     CCS       CAD          HB        108/80              70/41               33/34                                   5/5         173/116     43/44      Y (0.556)   6           

  Nassar-a \[[@B16]\]           2008                Canada    CCS       CAD          PB        149/149             73/63               63/69                                   13/17       209/195     89/103     Y (0.772)   7           

  Nassar-b \[[@B16]\]           2008                Canada    CCS       CAD          PB        150/149             58/63               77/69                                   15/17       193/195     107/103    Y (0.772)   8           

  Zhang \[[@B29]\]              2008                China     CCS       ICVD         PB        165/150             122/132             40/18                                   3/0         284/282     46/18      Y (0.434)   8           

  Zheng \[[@B31]\]              2008                China     CCS       CAA          HB        117/93              69/53               33/32                                   15/8        171/138     63/48      Y (0.328)   6           

  Kimouli \[[@B9]\]             2009                Greece    CCS       CAA          PB        150/151             82/73               59/64                                   9/14        223/210     77/92      Y (0.996)   8           

  Matzhold \[[@B12]\]           2009                Austria   CCS       CAD          PB        2565/728            1374/372            1012/283                                179/73      3760/1027   1370/429   Y (0.081)   7           

  Xiao \[[@B28]\]               2010                China     CCS       CAD          PB        139/90              126/68              13/19                                   0/3         265/155     13/25      Y (0.265)   7           

  Zhang \[[@B30]\]              2010                China     CCS       CI           PB        120/102             81/51               35/43                                   4/8         197/145     43/59      Y (0.798)   7           

  Zhao \[[@B23]\]               2010                China     CCS       CAA          HB        318/292             194/164             66/65                                   58/63       454/393     182/191    N (0.000)   7           

  Li \[[@B11]\]                 2012                China     CCS       CI           PB        308/294             289/280             19/14                                   0/0         597/574     19/14      Y (0.676)   8           

  Shi \[[@B26]\]                2012                China     CCS       CI           HB        563/563             497/512             52/44                                   14/7        1046/1068   80/58      N (0.000)   7           

  Singh-a \[[@B21], [@B22]\]    2012                India     CCS       CAD          PB        152/300             111/150             37/118                                  4/32        259/418     45/182     Y (0.230)   8           

  Singh-b \[[@B21], [@B22]\]    2012                India     CCS       CAD          PB        156/300             96/150              48/118                                  12/32       240/418     72/182     Y (0.230)   8           

  Singh-c \[[@B21], [@B22]\]    2012                India     CCS       AMI          PB        230/300             157/150             61/118                                  12/32       375/419     85/182     Y (0.230)   7           

  Wu \[[@B27]\]                 2012                China     CCS       IS           PB        163/100             119/88              41/12                                   3/0         279/188     47/12      Y (0.523)   7           

  Pucci-a \[[@B19]\]            2013                Italy     CCS       AMI          HB        25/22               13/2                10/12                                   2/8         36/16       14/28      Y (0.402)   7           

  Pucci-b \[[@B19]\]            2013                Italy     CCS       AMI          HB        16/22               1/2                 10/12                                   5/8         12/16       20/28      Y (0.402)   7           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CCS: case-control study, CS: cohort study, SS: sample size, PB: population-based, HB: hospital-based, HWE: Hardy-Weinberg equilibrium, Y: yes, N: no, AMI: acute myocardial infarction, CAA: carotid artery atherosclerosis, CAD: coronary artery disease, CI: cerebral infarction, ICVD: ischemic cerebrovascular disease, IS: ischemic stroke, PAD: peripheral arterial disease.

###### 

Meta-analyses of *CX3CR1* T280M and V249I polymorphisms and risk of AS in each subgroup.

  Position                                        SS (case/control)   Dominant model        Recessive model   Codominant model      Additive model   Allelic model                                                                       
  ----------------------------------------------- ------------------- --------------------- ----------------- --------------------- ---------------- --------------------- -------- --------------------- -------- --------------------- --------
  Overall analysis                                                                                                                                                                                                                       
  T280M                                           7732/5905           0.83 \[0.68, 1.02\]   0.08              1.01 \[0.82, 1.26\]   0.91             0.81 \[0.67, 0.99\]   0.04     0.96 \[0.77, 1.19\]   0.72     0.88 \[0.73, 1.05\]   0.16
  V249I                                           7952/6035           0.84 \[0.71, 0.98\]   0.03              0.88 \[0.69, 1.11\]   0.27             0.87 \[0.76, 0.99\]   0.04     0.81 \[0.62, 1.05\]   0.12     0.86 \[0.75, 0.99\]   0.04
                                                                                                                                                                                                                                         
  Subgroup analysis based on ethnicity                                                                                                                                                                                                   
  T280M (C)                                       5193/3241           0.83 \[0.69, 0.99\]   0.04              0.97 \[0.74, 1.28\]   0.85             0.82 \[0.68, 0.98\]   0.03     0.94 \[0.71, 1.23\]   0.64     0.87 \[0.75, 1.01\]   0.06
  T280M (A)                                       2539/2664           0.92 \[0.60, 1.43\]   0.72              1.09 \[0.76, 1.56\]   0.66             0.88 \[0.58, 1.32\]   0.54     1.00 \[0.70, 1.44\]   0.99     0.98 \[0.66, 1.47\]   0.93
  V249I (C)                                       5413/3371           0.91 \[0.81, 1.03\]   0.15              0.96 \[0.72, 1.28\]   0.79             0.94 \[0.86, 1.03\]   0.18     0.92 \[0.67, 1.27\]   0.62     0.92 \[0.82, 1.04\]   0.19
  V249I (A)                                       2539/2664           0.80 \[0.57, 1.14\]   0.22              0.75 \[0.48, 1.16\]   0.19             0.84 \[0.63, 1.13\]   0.25     0.66 \[0.40, 1.09\]   0.10     0.84 \[0.62, 1.15\]   0.28
                                                                                                                                                                                                                                         
  Subgroup analysis based on type of diseases                                                                                                                                                                                            
  T280M (CAD)                                     4768/2984           0.67 \[0.52, 0.85\]   \<0.01            0.69 \[0.51, 0.93\]   0.01             0.68 \[0.53, 0.88\]   \<0.01   0.64 \[0.48, 0.87\]   \<0.01   0.70 \[0.58, 0.86\]   \<0.01
  T280M (PAD)                                     492/503             0.88 \[0.68, 1.14\]   0.34              1.38 \[0.64, 2.94\]   0.41             0.84 \[0.64, 1.10\]   0.20     1.31 \[0.61, 2.80\]   0.49     0.94 \[0.75, 1.17\]   0.56
  T280M (CAA)                                     693/740             0.73 \[0.43, 1.23\]   0.23              0.98 \[0.60, 1.60\]   0.94             0.68 \[0.41, 1.14\]   0.15     0.89 \[0.55, 1.46\]   0.65     0.81 \[0.52, 1.25\]   0.33
  T280M (ICVD)                                    1779/1678           1.58 \[0.98, 2.53\]   0.06              2.83 \[1.62, 4.95\]   \<0.01           1.43 \[0.88, 2.31\]   0.15     2.90 \[1.65, 5.07\]   \<0.01   1.65 \[1.06, 2.55\]   0.03
  V249I (CAD)                                     4990/3115           0.69 \[0.55, 0.86\]   \<0.01            0.70 \[0.53, 0.92\]   0.01             0.79 \[0.66, 0.94\]   \<0.01   0.62 \[0.43, 0.87\]   \<0.01   0.72 \[0.59, 0.87\]   \<0.01
  V249I (PAD)                                     492/503             1.01 \[0.79, 1.30\]   0.94              1.38 \[0.81, 2.35\]   0.24             0.94 \[0.73, 1.21\]   0.63     1.36 \[0.78, 2.34\]   0.28     1.05 \[0.86, 1.28\]   0.62
  V249I (CAA)                                     693/740             0.82 \[0.66, 1.01\]   0.07              1.02 \[0.65, 1.60\]   0.94             0.82 \[0.65, 1.03\]   0.09     0.93 \[0.61, 1.40\]   0.71     0.87 \[0.74, 1.03\]   0.11
  V249I (ICVD)                                    1777/1677           1.29 \[0.83, 2.01\]   0.25              1.50 \[0.78, 2.90\]   0.23             1.22 \[0.80, 1.85\]   0.35     1.44 \[0.65, 3.17\]   0.37     1.33 \[0.89, 1.99\]   0.16
                                                                                                                                                                                                                                         
  Subgroup analysis based on source of controls                                                                                                                                                                                          
  T280M (HB)                                      3288/3094           0.89 \[0.71, 1.13\]   0.34              1.30 \[0.97, 1.74\]   0.08             0.86 \[0.70, 1.06\]   0.16     1.27 \[0.95, 1.70\]   0.11     0.94 \[0.75, 1.17\]   0.56
  T280M (PB)                                      4444/2811           0.81 \[0.57, 1.14\]   0.22              0.74 \[0.54, 1.03\]   0.07             0.80 \[0.57, 1.13\]   0.21     0.68 \[0.49, 0.94\]   0.02     0.84 \[0.63, 1.13\]   0.25
  V249I (HB)                                      3505/3222           0.91 \[0.78, 1.06\]   0.22              1.13 \[0.86, 1.49\]   0.37             0.89 \[0.80, 1.00\]   0.04     1.08 \[0.79, 1.48\]   0.64     0.94 \[0.82, 1.09\]   0.42
  V249I (PB)                                      4447/2813           0.80 \[0.59, 1.09\]   0.15              0.62 \[0.48, 0.81\]   \<0.01           0.88 \[0.68, 1.15\]   0.35     0.55 \[0.38, 0.78\]   \<0.01   0.81 \[0.63, 1.04\]   0.10
                                                                                                                                                                                                                                         
  Sensitivity analysis                                                                                                                                                                                                                   
  T280M (BS)                                      7507/5732           0.81 \[0.66, 1.00\]   0.05              0.99 \[0.79, 1.23\]   0.90             0.80 \[0.65, 0.98\]   0.03     0.93 \[0.75, 1.16\]   0.52     0.86 \[0.71, 1.03\]   0.10
  T280M (BH)                                      6851/5050           0.82 \[0.66, 1.00\]   0.06              0.97 \[0.74, 1.23\]   0.79             0.80 \[0.65, 0.99\]   0.04     0.91 \[0.72, 1.16\]   0.47     0.85 \[0.71, 1.03\]   0.09
  V249I (BS)                                      7727/5862           0.84 \[0.71, 1.00\]   0.05              0.86 \[0.67, 1.10\]   0.23             0.89 \[0.77, 1.02\]   0.09     0.79 \[0.60, 1.05\]   0.11     0.86 \[0.74, 1.00\]   0.06
  V249I (BH)                                      6579/4677           0.80 \[0.67, 0.97\]   0.02              0.82 \[0.62, 1.07\]   0.14             0.85 \[0.73, 0.99\]   0.04     0.74 \[0.54, 1.00\]   0.05     0.83 \[0.71, 0.98\]   0.03

A: Asians; C: Caucasians; CAD: coronary artery disease; CAA: carotid artery atherosclerosis; ICVD: ischemic cerebrovascular disease; PAD: peripheral arterial disease; PB: population-based, HB: hospital-based; BS: based on score (studies with score ≤ 6 were excluded); BH: based on HWE (studies without HWE were excluded). Bonferroni correction was used to control for the multiple testing in view of five genetic models under investigation (significance was set at 0.05/5 = 0.01).

###### 

The independent effect of each genotype/haplotype on susceptibility to atherosclerosis.

  Genotype    Cases (*n*)   Controls (*n*)   Baseline risk   OR      95% CI        *P*       *I* ^2^ (%)   *P* ~*Q*~
  ----------- ------------- ---------------- --------------- ------- ------------- --------- ------------- -----------
  VVTT        1923          2601                             1                                              
  VVTM        49            3                VVTT            11.95   5.00--28.58   \<0.001   0             0.44
  VITT        516           700              VVTT            1.11    0.96--1.27    0.16      31.4          0.13
  VITM        605           1211             VVTT            0.64    0.50--0.82    \<0.001   69.2          \<0.1
  IITT        64            76               VVTT            1.20    0.83--1.74    0.33      0             0.46
  IITM        100           182              VVTT            0.69    0.52--0.90    \<0.01    41.7          \<0.1
  IIMM        87            151              VVTT            0.76    0.57--1.02    0.06      0             0.79
  VV          4813          3556                             1                                              
  VI          2598          2016             VV              0.84    0.72--0.98    0.02      65.9          \<0.1
  VI (CAD)    1843          1227             VV (CAD)        0.72    0.59--0.90    \<0.01    68.1          \<0.1
  II          541           463              VV              0.81    0.62--1.05    0.12      61.6          \<0.1
  TT          5786          4293                             1                                              
  TM          1743          1456             TT              0.81    0.66--0.99    0.04      76.2          \<0.1
  TM (CAD)    1193          871              TT (CAD)        0.67    0.52--0.87    \<0.01    72.2          \<0.1
  MM          203           156              TT              0.96    0.77--1.19    0.72      31.9          0.08
  MM (ICVD)   47            16               TT (ICVD)       2.88    1.64--5.04    \<0.001   0             0.92
  VT          5377          6975                             1                                              
  VM          77            5                VT              11.47   5.34--24.64   \<0.001   43.0          0.12
  IT          814           1007             VT              1.09    0.97--1.21    0.14      0             0.55
  IM          892           1665             VT              0.63    0.50--0.81    \<0.001   82.2          \<0.1

*P* ~*Q*~, *P* value for Cochran\'s *Q* statistic.

###### 

Estimated haplotype frequencies and linkage disequilibrium analysis of the included studies.

  First author                    Estimated haplotype frequencies (cases)   Estimated haplotype frequencies (controls)   *D*′^a^   *r* ^2^ ^a^                                                
  ------------------------------- ----------------------------------------- -------------------------------------------- --------- ------------- -------- -------- -------- -------- -------- --------
  McDermott \[[@B13], [@B14]\]    0.7817                                    0                                            0.0838    0.1345        0.7042   0        0.0986   0.1972   1        0.5848
  Moatti \[[@B15]\]               0.7980                                    0                                            0.0993    0.1026        0.7149   0        0.1345   0.1506   1        0.4445
  Gugl \[[@B8]\]                  0.7317                                    0                                            0.0904    0.1778        0.7416   0        0.0706   0.1879   1        0.6638
  McDermott \[[@B13], [@B14]\]    0.7304                                    0                                            0.1324    0.1373        0.7018   0        0.1157   0.1825   1        0.5253
  Ghilardi \[[@B7]\]              0.7407                                    0                                            0.1481    0.1111        0.7255   0        0.1225   0.1520   1        0.4736
  Hattori \[[@B50]\]              0.9318                                    0.0256                                       0.0065    0.0361        0.9444   0.0082   0.0033   0.0441   0.9270   0.7743
  Niessner \[[@B17], [@B18]\]     0.7332                                    0.0016                                       0.1113    0.1540        0.7564   0        0.0998   0.1439   1        0.5217
  Apostolakis \[[@B6], [@B43]\]   0.7214                                    0                                            0.1500    0.1286        0.7000   0        0.1212   0.1788   1        0.508
  An \[[@B24]\]                   0.8241                                    0                                            0.0833    0.0926        0.7187   0        0.1250   0.1562   1        0.4733
  Nassar-a \[[@B16]\]             0.7067                                    0.0171                                       0.1440    0.1321        0.6544   0        0.1376   0.2081   1        0.4974
  Nassar-b \[[@B16]\]             0.6250                                    0.0203                                       0.1622    0.1925        0.6544   0        0.1376   0.2081   1        0.4974
  Zhao \[[@B23]\]                 0.7138                                    0                                            0.1478    0.1384        0.6729   0        0.1353   0.1918   1        0.4882
  Singh-a, b \[[@B21], [@B22]\]   0.7559                                    0.0542                                       0.1402    0.0497        0.6967   0        0.1050   0.1983   1        0.5682
  Singh-c \[[@B21], [@B22]\]      0.7739                                    0.0413                                       0.1304    0.0543        0.6967   0        0.1050   0.1983   1        0.5682
                                                                                                                                                                                              
  Total                           0.7477                                    0.0091                                       0.1120    0.1312        0.7224   0.0006   0.1050   0.1720   0.9950   0.5394

^a^ *D*′ and *r* ^2^ statistics refer to control groups.

[^1]: Academic Editor: Luisella Bocchio-Chiavetto
